Lemonade, Inc. (LMND): what the price requires

The current priced-in claim for Lemonade, Inc. (LMND) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/LMND

Headline

FieldValue
TickerLMND
CompanyLemonade, Inc.
Current price$69.96/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Price-to-book10.38x

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 17.4% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

How unusual the bet is: extreme

ReferenceValue
vs own history+10.00σ
cohort percentile (of 80 peers)96
sustained it ~10 years at this level24%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset10.88x2expensive
Earnings—0—
Relative5.27x1expensive
Growth1.27x2expensive

Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.5%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)———no—
Relative ValuationRelative$13.285.27xyesP/S fallback (negative EPS): Sector P/S 1.2x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$6.7910.30xyesBook value floor: BV/sh $6.79, ROE negative
Two-Stage Excess ReturnAsset$6.1111.45xyesBook value with convergence: BV/sh $6.79, ROE converges to ke
Discounted Future Market CapGrowth$101.510.69xyesRev $0.8B, growth 30% (input: historical growth; tapered), Terminal P/S: 5.1x / 6.3x / 7.6x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$37.741.85xyesMargin ramp: -16% → 10% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)5.5%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Start with the bear's strongest objection, because confronting it is the cleanest way to see the bull case: Lemonade still loses money, and the price pays a steep multiple of book for a company that has never earned a sustained return. That is true, and yet the trajectory is doing exactly what an insurance startup needs it to do. The single most important number in insurance is the loss ratio, the share of premium paid out in claims, and Lemonade's gross loss ratio improved to 62% in the most recent quarter from 78% a year earlier. That is not a marketing metric; it is the engine of insurance profitability, and a 16-point improvement in a year is the difference between a business that cannot work and one that is converging on one. The fear the price embeds is that Lemonade never reaches underwriting profit. The data is moving the other way.

The growth underneath that improving underwriting is real and broadening. In-force premium grew 32% to $1.33 billion, the customer count grew 23% to about 3.1 million, and revenue grew 71% to $258 million as premium retention and per-customer value rose. Crucially, gross profit grew 159% to $100 million, lifting gross margin to 39%, which means the unit economics are scaling faster than the top line, the operating-leverage signature of a platform crossing toward profitability. The 10-K shows this compounding over time, with gross profit margin rising as "multiple policies per customer" and a shift "toward higher value policies" raise the average premium per customer. The AI claims-and-underwriting model is the cost advantage: a digitally native insurer that automates the expensive human-labor parts of insurance can, at scale, run a leaner expense ratio than incumbents built on branches and adjusters.

The float optionality is the part the static methods cannot price. An insurer collects premiums before it pays claims, and that timing gap is investable capital. The 10-K notes Lemonade expects "net investment income will represent a more meaningful component of our results of operations" as the book grows. A larger in-force premium base means a larger float, and in a normal-rate environment that float generates investment income on top of underwriting profit, the two-engine model that makes mature insurers durable compounders. The bull case is that Lemonade is months, not years, from the inflection where an improving loss ratio, scaling gross margin, and a growing float combine into sustained profitability, and management's guidance for positive adjusted EBITDA by the fourth quarter is the milestone that would validate it.

Bear Case

The structural problem is the gap between what the balance sheet has demonstrated and what the price assumes about it. Lemonade carries book value of about $6.79 a share and the stock trades near $59 (as of June 27, 2026), nearly nine times book, which for an insurer is an extraordinary multiple because an insurer is fundamentally worth the return it earns on its capital. The trouble is that Lemonade's return on that capital is still negative: the company is losing money, so the multiple it commands is not supported by any sustainable return record. The price pays a multiple of book that, translated into the return it would require, is so far above anything an insurer has ever sustained that the figure is not meaningfully expressible. That is the most demanding end of the valuation scale, and it rests entirely on a future profitability the company has not yet produced.

The fragility is specific to the insurance model. An insurer's capital is its shock absorber: it must hold reserves against the claims it has written, and a thin capital base relative to the premium it underwrites leaves little room for error. Lemonade is growing its in-force premium at roughly 30% a year on a book value that, after years of losses, remains modest, which means it is leaning hard on reinsurance to support the growth and on continued access to capital markets to fund the cash burn until profitability arrives. The net loss narrowed but persisted at $35.8 million in the quarter, and the company has been diluting shareholders, with the share count rising about 5.5% a year, to fund the journey. A company that must keep raising or retaining capital to grow is exposed precisely when capital is most expensive, and a stock at nine times book has no cushion if a hard catastrophe quarter or a capital-markets freeze interrupts the path.

The competitive and underwriting risks compound the capital risk. Lemonade competes against insurers with decades of actuarial data, deeper balance sheets, and their own AI investments, and insurance is a business where the incumbents' scale in data is itself a moat. The loss-ratio improvement is encouraging, but a single bad catastrophe season, or adverse reserve development as the newer car-insurance and homeowners books season, could reverse it, and the price gives no weight to that volatility. The 10-K's own framing of the business, still building toward the point where investment income is meaningful, is an acknowledgment that the mature two-engine insurance model is ahead, not present. The bear case does not require Lemonade to fail. It requires only that the path to durable underwriting profit takes longer, costs more capital, or proves bumpier than a nine-times-book price assumes, and the history of insurance startups says that is the base case, not the tail.

Valuation

An insurer is worth the return it earns on its capital, so the right lens is price-to-book, not an operating multiple, and Lemonade trades at roughly nine times book. At that price the implied return on capital is so far above anything an insurer has sustainably earned that no single figure honestly expresses it. The bet, stated plainly, is that Lemonade transforms from a loss-making growth company into a durably profitable insurer earning a return that justifies a multiple of book that sits at the very top of the entire insurance peer group. This is the most demanding valuation in the insurance cohort.

The method pattern reflects a pre-profit company priced on its future. Only the forward-growth lens reaches the price, and it does so by crediting Lemonade's roughly 50% revenue growth carried forward. The static frames cannot get there. The asset-value methods anchor on book value of $6.79 a share, a small fraction of the price, because with a negative return on equity the excess-return methods generate no premium over book at all. The peer-multiple lens, forced onto a price-to-sales basis because earnings are negative, lands at roughly a quarter of the price. The earnings-power family does not even apply, because there is no positive earnings power to capitalize. The honest read is that the demonstrated economics support a price near book value, and the entire gap to today's price is the market crediting a profitability inflection that has not yet happened.

The cohort comparison underscores how unusual the multiple is. The peer set, specialty and growth insurers like Palomar, SiriusPoint, HCI Group, White Mountains, and Hamilton Insurance, trades at multiples of book appropriate to insurers that already earn returns, and Lemonade sits far above that group on a book multiple while earning less than they do. The insurance solvency frame is regulatory capital and reserve adequacy, not corporate leverage: the relevant questions are whether the capital base supports the premium growth and whether reserves are adequate as the book seasons, and a thin book funded partly by dilution is the pressure point. The decisive fact is the loss ratio against the multiple. The improving loss ratio is the reason to believe the inflection is coming; the nine-times-book price is the reason the margin for it arriving late is so small. The buyer is underwriting not just that Lemonade becomes profitable, but that it becomes profitable enough, fast enough, to validate the most demanding multiple in its sector.

Catalysts

The Q1 2026 print showed faster growth and smaller losses, the exact combination the thesis needs, yet the stock fell sharply afterward, which says the bar was high. In-force premium grew 32% to $1.33 billion, customers grew 23% to about 3.1 million, and revenue grew 71% to $258 million. The underwriting improvement was the headline: the gross loss ratio improved to 62% from 78% and the net loss ratio to 63% from 82%, while gross profit grew 159% to $100 million at a 39% margin. The net loss narrowed to $35.8 million from $62.4 million and the adjusted EBITDA loss improved to $17.1 million from $47.0 million, both meaningful steps toward the profitability inflection.

Guidance set the milestones to watch. Management called for full-year in-force premium of $1.63 to $1.64 billion and revenue of about $1.20 billion, and reiterated the target of positive adjusted EBITDA in the fourth quarter of 2026 with full-year EBITDA profitability in 2027. Those two dates are the concrete catalysts: hitting Q4 2026 adjusted EBITDA breakeven would be the first hard evidence that the model works at scale, and missing it would extend the capital-burn window the bear case turns on.

The watch items are the insurance-specific ones. Track the loss-ratio trajectory across seasons, since a single catastrophe-heavy quarter can interrupt the trend, and watch the newer car-insurance and homeowners books as they season, because adverse reserve development there would undercut the improvement story. Beyond underwriting, the markers are the cash-burn pace against the capital base and any need to raise equity, since the gap between a loss-making present and a nine-times-book price is exactly the window in which financing risk lives. For this name, the catalyst that matters most is not the next premium number but the next loss-ratio and EBITDA number, because those are what convert the growth story into the profit the valuation already assumes.

Peer Cohorts (Per Segment, With Filing Citations)

Personal property and casualty insurance (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 FY2026 earnings release · FY2024 10-K

View the full interactive LMND report on boothcheck